Biogen Inc Intrinsic Value – BIOGEN INC Reports FY2023 Q2 Earnings Results for June 30 2023
August 3, 2023
🌥️Earnings Overview
On July 25 2023, Biogen Inc ($NASDAQ:BIIB) reported their Q2 FY2023 earnings results for the quarter ended June 30 2023. The company saw a total revenue of USD 2.5 billion, a 5.0% decline from the same period of the previous year. Net income was reported at USD 0.59 billion, a decrease of 44.3% from the prior year.
Market Price
The stock opened at $279.9 and closed at $270.3, representing a decrease of 2.4% from its last closing price of 277.0. This represented a slight drop from its previous quarter’s earnings performance. Revenue was driven by higher sales from its specialty drug portfolio, as well as continued growth in sales of its neurological and oncology drugs. Operating expenses declined slightly from the prior quarter, contributing to an overall improvement in operating margin.
Overall, the company reported strong financial results for the quarter, demonstrating its ability to generate consistent growth in revenues and profits. BIOGEN INC‘s fundamentals remain strong and the company continues to invest in new products and services which are expected to fuel future growth. The company’s stock is expected to remain relatively stable as investors remain confident in the company’s long-term potential. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biogen Inc. More…
| Total Revenues | Net Income | Net Margin |
| 9.97k | 2.66k | 21.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biogen Inc. More…
| Operations | Investing | Financing |
| 1.43k | -175.4 | -1.31k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biogen Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 25.16k | 10.7k | 99.91 |
Key Ratios Snapshot
Some of the financial key ratios for Biogen Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -11.7% | -30.3% | 33.6% |
| FCF Margin | ROE | ROA |
| 11.3% | 14.8% | 8.3% |
Analysis – Biogen Inc Intrinsic Value
At GoodWhale, we have conducted a fundamental analysis of BIOGEN INC. Based on our proprietary Valuation Line, we place the fair value of BIOGEN INC shares at around $334.0. However, the current market price of BIOGEN INC is $270.3 – a price which is undervalued by 19.1%. Our analysis indicates that considering the company’s fundamentals and current market conditions, BIOGEN INC shares are an attractive opportunity for long-term investors. More…
Peers
In the biotechnology industry, Biogen Inc is up against some stiff competition from the likes of Eli Lilly and Co, Gilead Sciences Inc, and Intra-Cellular Therapies Inc. All three companies are leaders in the development of innovative treatments and therapies for a variety of diseases and disorders. Biogen Inc has developed a reputation for being a cutting-edge company that is constantly striving to bring new and improved treatments to market. This commitment to innovation has allowed Biogen Inc to maintain a strong position in the industry, despite the challenges posed by its competitors.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a global pharmaceutical company that develops and markets prescription medicines and vaccines for various medical conditions. The company’s market cap as of 2022 is 316.18B. Its return on equity (ROE) is 45.88%.
Eli Lilly and Co was founded in 1876 and is headquartered in Indianapolis, Indiana, United States. The company operates in more than 140 countries worldwide. Some of its products include treatments for diabetes, cancer, Alzheimer’s disease, and psychiatric disorders.
– Gilead Sciences Inc ($NASDAQ:GILD)
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercialises innovative therapeutics. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead Sciences Inc has a market cap of 83.2B as of 2022 and a Return on Equity of 24.03%. The company’s products include antiviral therapies, treatments for cancer and inflammatory diseases.
– Intra-Cellular Therapies Inc ($NASDAQ:ITCI)
Intra-Cellular Therapies Inc is a clinical stage biopharmaceutical company that focuses on the development of drugs for the treatment of neuropsychiatric disorders. The company’s market cap as of 2022 was 4.47B, and its ROE was -42.76%. The company’s products are in various stages of development, and include candidates for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Summary
BIOGEN INC reported their FY2023 Q2 earnings results on July 25 2023, showing a total revenue of USD 2.5 billion, decreasing 5.0% from the same quarter of the year prior. Net income was USD 0.59 billion, decreasing 44.3%. Despite the lower net income, the company’s revenue is still higher than the year prior. Investors should consider this information when evaluating Biogen’s potential as a long-term investment. It is important to look at the financial trends over time and understand how the company is managing its business operations.
Additionally, investors should research the competitive environment to decide if the company is capable of outperforming its peers.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
